Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Apogee Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$1,881,989

102 payments

Through program year 2025, Apogee Clinical Research LLC is reported as receiving $1,881,989 in research payments, across 102 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $902,749 26
2024 Research $368,425 35
2023 Research $461,447 38
2022 Research $149,369 3

Breakdown

Who paid Research payments · program years 2022–2025
  1. Eli Lilly and Company $703,834 5 payments
  2. AstraZeneca Pharmaceuticals LP $661,326 8 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $209,769 80 payments
  4. AstraZeneca UK Limited $176,727 3 payments
  5. Vertex Pharmaceuticals Incorporated $91,733 1 payment
  6. Alexion Pharmaceuticals, Inc. $19,340 3 payments
  7. Novartis Pharmaceuticals Corporation $19,260 2 payments
Studies the money was for Research payments · program years 2022–2025
  1. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index Greater Than 27 KG M2 and Atherosclerotic Cardiovascular Disease and Or Chronic Kidney Disease $609,106 3 payments
  2. A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria $330,922 2 payments
  3. The purpose of the D4325C00007 study is to identify and characterise patients with known or newly diagnosed CKD for possible participation in future renal clinical studies and to obtain an overview on current treatment choices for this patient group in different regions $182,068 2 payments
  4. A Phase 2b multicentre randomized double-blind placebo-controlled parallel group dose ranging study to assess the efficacy safety and tolerability of zibotentan and dapagliflozin in patients with chronic kidney disease with estimated glomerular filtration rate eGFR between 20 and 60 mL min 1.73 m2 $176,727 3 payments
  5. A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes, Moderate Or Severe Renal Impairment With Inadequate Glycemic Control on Basal Insulin With Or Without Metformin And/Or Sglt2 Inhibitor $94,728 2 payments
  6. A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Povetacicept in Adults With Immunoglobulin A Nephropathy (RAINIER) $91,733 1 payment
  7. Cardiovascular Renal and Metabolism Lokelma Hyperkalemia $78,271 2 payments
  8. BAY94-8862, Finerenone Phase 3 in non-diabetic CKD $73,970 19 payments
  9. A Randomized, Double Blind, Placebo Controlled, Multicenter, Parallel Group, Dose Ranging Study to Evaluate CIN 107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease $70,066 2 payments
  10. Fine-Real $58,447 12 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record